Elisabet Granstam1, Inger Westborg2, Anna Barkander3, Malin Börjesson4, Sara Lindahl5, Eva Meszaros6, Anna Wojciechowska-Zajac7, Philippe Wagner8, Susanne Albrecht9, Niklas Karlsson9, Gunilla Bjärnhall9, Monica Lövestam-Adrian10. 1. Center for Clinical Research, Uppsala University/County Council of Västmanland, Västerås, Sweden. elisabet.granstam@ltv.se. 2. Department of Clinical Science/Ophthalmology, Umeå University, Umeå, Sweden. 3. Department of Ophthalmology, Östersund County Hospital, Östersund, Sweden. 4. Department of Ophthalmology, Skellefteå County Hospital, Skellefteå, Sweden. 5. Department of Ophthalmology, Umeå University Hospital, Umeå, Sweden. 6. Department of Ophthalmology, Gävleborg County Hospital/Gävle, Gävle, Sweden. 7. Department of Ophthalmology, Sunderby County Hospital, Sunderbyn, Sweden. 8. Center for Clinical Research, Uppsala University/County Council of Västmanland, Västerås, Sweden. 9. Swedish Macula Register, RC Syd, Karlskrona, Sweden. 10. IKVL Institution of Clinical Science, Ophthalmology, Lund University, Lund, Sweden.
Abstract
PURPOSE: To study the occurrence of severe visual impairment (SVI) and treatment outcome at 12 months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties. METHODS: Referrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12 months from the SMR database from 2008 until 2013 in patients >65 years of age in five northern counties were included in the survey. RESULTS: The rate of referral due to AMD was significantly reduced during the time period (-48%; p < 0.001). At 12 months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (-0.01, SD 0.37; p < 0.001) after a mean of 5.0 ± 2.3 anti-vascular endothelial growth factor (VEGF)-injections were administered. Age and low baseline VA was associated with less favourable visual outcome (p < 0.001). CONCLUSION: Referral rate to low vision clinic is a valuable tool for estimating occurrence of SVI and fell between the years 2005 until 2013. Data from the SMR showed improvement in visual acuity on the whole, but also identified patients at high risk for developing SVI during anti-VEGF-treatment.
PURPOSE: To study the occurrence of severe visual impairment (SVI) and treatment outcome at 12 months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties. METHODS: Referrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12 months from the SMR database from 2008 until 2013 in patients >65 years of age in five northern counties were included in the survey. RESULTS: The rate of referral due to AMD was significantly reduced during the time period (-48%; p < 0.001). At 12 months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (-0.01, SD 0.37; p < 0.001) after a mean of 5.0 ± 2.3 anti-vascular endothelial growth factor (VEGF)-injections were administered. Age and low baseline VA was associated with less favourable visual outcome (p < 0.001). CONCLUSION: Referral rate to low vision clinic is a valuable tool for estimating occurrence of SVI and fell between the years 2005 until 2013. Data from the SMR showed improvement in visual acuity on the whole, but also identified patients at high risk for developing SVI during anti-VEGF-treatment.
Authors: Paola S Calles-Monar; María R Sanabria; Ana M Alonso-Tarancon; Rosa M Coco-Martin; Agustín Mayo-Iscar Journal: Drugs Aging Date: 2022-04-29 Impact factor: 3.923
Authors: Johanna M Colijn; Gabriëlle H S Buitendijk; Elena Prokofyeva; Dalila Alves; Maria L Cachulo; Anthony P Khawaja; Audrey Cougnard-Gregoire; Bénédicte M J Merle; Christina Korb; Maja G Erke; Alain Bron; Eleftherios Anastasopoulos; Magda A Meester-Smoor; Tatiana Segato; Stefano Piermarocchi; Paulus T V M de Jong; Johannes R Vingerling; Fotis Topouzis; Catherine Creuzot-Garcher; Geir Bertelsen; Norbert Pfeiffer; Astrid E Fletcher; Paul J Foster; Rufino Silva; Jean-François Korobelnik; Cécile Delcourt; Caroline C W Klaver Journal: Ophthalmology Date: 2017-07-14 Impact factor: 12.079